Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease
Status:
Recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
There is no standard of care therapy for patients with granulomatous-lymphocytic interstitial
lung disease (GLILD) seen in common variable immunodeficiency (CVID). Abatacept has recently
looked promising for the treatment of patients with complex CVID. This study is a multi-site,
phase II, randomized, blinded/placebo-controlled clinical trial in pediatric and adult
subjects to determine the efficacy of abatacept compared to placebo for treatment of subjects
with GLILD in the context of CVID.